TOURMALINE-MM1: new oral triplet combination for patients with relapsed/refractory multiple myeloma
The treatment of multiple myeloma (MM) radically changed 11 years ago when the addition of Thalidomide to Melphalan-Prednisone (MPT) was proven to be superior to Melphalan-Prednisone (MP) alone (1). Various other compounds have been approved since, changing the landscape of MM treatment at diagnosis and in the relapse setting. Despite all these improvements, the vast majority of patients still relapse and the management of this group of patients can be challenging. In particular those patients relapsing after Bortezomib and Lenalidomide (the backbone of treatment for MM) have a poor outcome with a median event-free survival (EFS) of 5 months and a median overall survival (OS) of 9 months (2).